Funding
← Back to your selection

T. Rowe Price Investment Management

Activity from announced rounds

Activity in this selectionOct 6, 2026 · AI · Jan 1, 2026
Rounds participated in
2
Confirmed lead rounds
0
1 roles undisclosed
New companies
2
First participation on record · 0 follow-on
Funding in participating rounds
$711M
2 disclosed · full round size, not this investor’s share

By stage

Series C+2

By primary sector

Biotech1
Hardware1

By country

United States2

Rounds

2 in this selection
Enveda

Enveda uses AI to discover biologically active molecules from nature and develop them into small-molecule medicines for inflammatory and metabolic diseases.

$311MSeries E
Participant
SiFive

SiFive licenses RISC-V processor intellectual property for custom computing chips, including high-performance data-centre designs.

$400MSeries G
Role not disclosed